assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non ... agent. Clinical trials that investigate the efficacy of bispecific ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape ... accompanied by significant clinical advancements. According to recent data, more than 85% of ...

In collaboration with TG Therapeutics, Light Chain has brought one internally developed κλ body, TG-1801 (formerly NI-1701), into clinical ... features of its bispecific antibody format ...

bispecific antibody, CTIM-76, has been dosed in the first patient in a Phase 1 clinical trial by its licensing partner, Context Therapeutics Inc. This milestone is part of a Phase 1 dose ...

a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem ...

This trial aims to evaluate the clinical potential of CS2009 in a wide range of advanced solid tumors including, but not limited to, non-small cell ... trispecific antibody designed and developed ...

announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.